PerkinElmer Stock Continues to Climb

Shares in PerkinElmer rose 5.54 percent for the five-day trading period ended Tuesday, continuing a steady ascent over recent weeks. The firm's shares closed at $21.15 on Tuesday, a price not reached since March 29, when PKI's shares rose as high as $21.97. Its low for the last three months was $18, which occurred on June 27. The volume of trading in the firm's shares was also relatively heavy early this week, though no news was announced.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.